A phase I study of alternate-day administration of S-1 plus leucovorin with bevacizumab in patients with refractory metastatic colorectal cancer.

ABSTRACT: Interventions: alternate-day administration of S-1 plus leucovorin with bevacizumab Primary outcome(s): recommended dose Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2631419 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR